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(1) Introduction 
It is said that the prostate was histologically acknowledged as an independent organ for 
the first time in the mid-nineteenth century.  No organ termed the prostate is indicated 
even in the world-renowned drawing of anatomy by Leonard da Vinci (1452 – 1519).  It 
was in 1941 that androgen depletion therapy (ADT) was reported as effective against 
prostate cancer.  For this achievement, Dr. Huggins received a Nobel Prize 25 years later 
in 1966.  At that time, most patients with prostate cancer who received ADT were in 
progressive stage.  As such, Dr. Huggins himself observed that recurrence was noted in 
many cases after several years of remission.  ADT was therefore classified as a palliative 
treatment.  Since PSA was discovered in 1979, the rate of detection of early-stage 
prostate cancer has rapidly improved.  Subsequently, in 1983, the method of anatomical 
prostatectomy was reported by Walsh, and established the concept of radical treatment of 
prostate cancer.  To be more precise, it became accepted that localized prostate cancer 
(LPC) and locally advanced prostate cancer (LAPC), the rate of detection of which 
sharply increased thanks to PSA screening, should be aggressively treated by radical 
methods including prostatectomy and radiotherapy.  However, the conclusion that ADT is 
a palliative method of treatment reached half a century ago is still accepted at present.  
As a result, this concept has been applied even to LPC and LAPC, and few careful clinical 
studies have been performed 1).  Despite the progress in ADT, including the 
establishment of theoretical grounds for maximal androgen blockade (or combined 
androgen blockade; MAB or CAB) and the development of a new nonsteroidal 
antiandrogen preparation, there has been little change in the concept of ADT as a palliative 
method of treatment of progressive prostate cancer, either. 
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(II) Current status of ADT 
The Prostate Cancer Treatment Guideline was published by the Japanese Urological 
Association in 2006 2).  As a member in charge of the drug therapy section of this edition, 
the author would like to report the current status of ADT by citing the abstract of the 
overview of this section. 
“At present, there is no chemotherapy superior to endocrine therapy for the treatment of 
prostate cancer.  Though the proximal effects of various endocrine therapies are 
remarkable, there is a limit to their indication since the effects of treatment persist for only 
for 2 to 3 years in progressive cases and because of the onset of sex-related adverse 
reactions including erectile dysfunction (ED) and decreased libido. 
The most generally applicable endocrine therapy is monotherapy with luteinizing 
hormone-releasing hormone (LH-RH) agonist or antiandrogen preparation, or concomitant 
treatment with these 2 drugs.  In treatment with LH-RH agonist, concomitant 
administration of an antiandrogen preparation should be considered if urinary tract 
obstruction caused by flare-up phenomenon associated with a transient increase in 
testosterone in the initial stage of administration, ostealgia due to a metastatic lesion, 
spinal compression, etc. are anticipated.  The efficacy of LH-RH agonist is considered 
equivalent to that of castration.  However, the efficacy of monotherapy with antiandrogen 
preparation is reported to be less than that of LH-RH, though no significant difference was 
observed.  On the other hand, antiandrogen preparations induce fewer sex-related adverse 
reactions.  Monotherapy with nonsteroidal antiandrogen preparations has therefore been 
reported to be useful, depending on patient status.  When the usefulness of bicalutamide 
as auxiliary therapy was investigated in LPC or LAPC in patients undergoing radical 
surgery, radiotherapy, and cautious observation of clinical course, prolongation of PSA 
doubling time and decrease in objective risk of progression were observed.  At present, a 
large-scale investigation of prolongation of survival period is proceeding.  In another 
investigation, whether chemo-endocrine therapy is more effective in treating Stage IV 
prostate cancer than endocrine monotherapy alone is being examined. 
The down-staging effect of neo-adjuvant hormonal therapy (NHT) is manifested as a 
decrease in frequency of cases with a positive resected stump or lymph node metastasis.  
Many randomized controlled studies (RCT) have confirmed the efficacy of NHT.  
However, since no clear evidence that NHT can improve survival rate has been obtained, 
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the results of analysis of long-term prognosis in each of these trials are awaited. 
Endocrine therapy is opted for in treating stage III-IV prostate cancer, and life-prolonging 
effects of it have been observed.  Endocrine therapy is sometimes performed in 
combination with surgery and radiotherapy in stage III cases.  Particularly since the 
report on the results of a RCT that survival period was prolonged more by concomitant 
radiotherapy and endocrine therapy than by radiotherapy alone, there has been much 
expectation regarding the efficacy of concomitant treatment.  However, there are 
problems in this regard, including the selection of appropriate patients, the appropriate 
time for initiation of endocrine therapy, the duration of treatment, and others.  In general, 
the standard treatment for progressive prostate cancer with metastasis is ADT by surgical 
or medical castration.  Since 40% of the androgen present in prostate gland cells appears 
to be derived from the adrenals, MAB was found to be useful due to inhibition of 
androgen from the testes and adrenals via castration (orchiectomy or LH-RH agonist 
administration) in combination with nonsteroidal antiandrogen preparation administration.  
Though MAB has been a generally accepted method of treatment of progressive prostate 
cancer, whether it can improve long-term prognosis in comparison with castration alone 
has been a subject of recent discussion.  According to the results of a meta-analysis 
recently performed, there is little difference in 2-year survival rate between MAB and 
monotherapy (castration or LH-RH agonist alone), though 5-year survival rate was 
significantly higher with MAB.  However, since the difference in survival rate is small, it 
appears that true clinical benefit should be determined considering adverse reactions, QOL, 
and cost.  At present, the results of further research demonstrating the validity of MAB 
are awaited.  Recently, the results of a double-blind study that compared MAB 
monotherapy using bicalutamide as antiandrogen preparation with LH—RH agonist 
monotherapy were reported.  Findings indicated a definite effect on time to progression. 
Even when recurrence of cancer is observed, discontinuation of antiandrogen preparation 
alone can in some cases transiently inhibit the progress of disease (antiandrogen 
withdrawal syndrome).  PSA decreased in 14 - 60% and a clinical effect was observed in 
0 - 25% of patients with discontinuation of antiandrogen preparation, or combination  
with hydrocortisone.  However, PSA reduction is reported to persist for only for 2 to 4 
months, in general. 
The above findings do not differ notably from those noted in the guidelines of the EAU or 
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NCI-PDQ.  However, the EAU and NCI-PDQ guidelines take a somewhat negative 
stance regarding use of ADT in the treatment of  LPC and LAPC. 
The current issues in use of ADT concern the following 3 points:  1) Though their 
number is still small, clinical studies based on new concepts (effects of MAB and 
intermittent androgen blockade therapy, etc.) are being performed.  Depending on the 
results of these studies, new conclusions regarding the role of ADT may be reached.  2) 
ADT is generally employed in Japan to treat LPC and LAPC (Fig. 1), and MAB is used in 
many cases (Fig. 2).  This tendency is definitely on the increase in the United States, as 
well (Fig. 3).  3) This choice of treatment is inconceivable if treatment method is selected 
according to the guidelines.  Why, then, does it exist? 
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Fig. 1 
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Prostate cancer registration data provided by the Japanese Urological Association are 
shown in this graph.   
Types of initial treatment as of 2000 for newly diagnosed patients are summarized.  
PADT was selected for 56.94% of cases of T1 through T4 disease.  For T1 through T3, 
PADT was still selected for 45.90% of cases. 
Cancer Registration Committee of the Japanese Urological Association. 
Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 Report 
from the Japanese Urological Association. 
Int J Urol. 2005;12:46-61. 
 
5
Fig. 2 
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Results of survey conducted by the Japan Prostate Cancer Study Group (JCaP) 
The results indicate that MAB is used as PADT in general in both low-risk and high-risk 
groups. 
Akaza H, Hinotsu S, Usami M, et al. Characteristics of patients with prostate cancer who 
have initially been treated by hormone therapy in Japan: J-CaP surveillance. 
Jpn J Clin Oncol. 2004;34:329-36. 
 
6
Fig. 3 
JUA 2007 Debate     Prostate Cancer                             University of Tsukuba
Trend of PADT for localized prostate cancer in U.S.A.  
(Cooperberg, et al. JNCI 2003)
 
USA CaPSURE data 
PADT is increasingly selected each year as a treatment against localized prostate cancer 
including the low risk and high risk groups.  However, the ratio is still lower in 
comparison with the PADT ratio in Japan (Fig. 1). 
Cooperberg MR, Grossfeld GD, Lubeck DF, Carroll PR. National practice patterns and 
time trends in androgen ablation for localized prostate cancer. 
J Natl Cancer Inst. 2003;95:981-9. 
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(III) Factors involved in the determination of method of treatment 
According to Mulrow 3), there are 3 types of factors that the physician and patient take into 
consideration in determining method of treatment (Fig. 4): (A) evidence, (B) 
patient/physician factors, and (C) constraints.  Referring to Fig. 4, guidelines are 
established based on A and C, while B and C are related to ethical aspects of treatment, 
and A and B involve knowledge.  Thus, the guidelines alone are not sufficient for 
determination of treatment in general clinical practice.  Ethical issues, education, 
experience, and personal sense of value and cultural factors are also involved in decisions 
regarding treatment.  In regard to the selection of endocrine therapy, there is less 
evidence, since only a few careful clinical studies have been performed.  If evidence is 
insufficient, neither affirmative nor negative judgments are possible regarding treatment 
methods generally used at present.  However, if this is the case, why is a negative stance 
taken in Europe and the United States regarding prostate androgen blockage monotherapy 
(PADT), and why is PADT increasingly performed at present despite this?  Why is PADT 
accepted more and why is MAB mostly employed in Japan? 
As shown in Fig. 4, elements B and C differ among countries, which has complex effects 
on the situation.  Fleming et al. 4) examined the relationships of prostatectomy, external 
radiotherapy, and observation of clinical course (slow ADT) to prognosis (death or onset 
of metastasis) of patients on the basis of the literature and medicare claims data.  Though 
surgery and radiotherapy are effective in young patients, there is not much benefit to them, 
and the benefit obtains varies among patients.  In fact, it has been concluded that the 
observation of clinical course (slow ADT) is a valid choice for patients over 70 years of 
age.  An astute observer may interpret this report as a warning against unnecessary 
surgery and radiotherapy under the influence of various requirements.  Similar findings 
have been reported by Miller et al. 5). 
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Fig. 4 
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Mulrow C, Langhome P, Grimshaw J. Integrating heterogeneous pieces of evidence in 
systematic reviews. 
Ann Intern Med. 1997;127:989-95. 
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(VI) Present-day ADT based on the Update of the 2006 ASCO Guidelines 
In April 2007, the 2004 edition of the ASCO treatment guidelines for PADT in recurrent or 
progressive prostate cancer with metastasis was updated 6).  In these guidelines, the 
following 5 issues are discussed on the basis of newly published clinical study results:  
(1) What are the standard initial treatment options?  (2) Are antiandrogens as effective as 
other castration therapies?  (3) Is combined androgen blockade better than castration 
alone?  (4) Does early androgen-deprivation therapy improve outcome compared with 
deferred therapy?  (5) Is intermittent androgen deprivation therapy better than continuous 
androgen deprivation therapy?  The essence of ADT is captured in each of these 5 issues.  
These issues are in addition important in assessing the usefulness of ADT in LPC and 
LAPC, the issue of greatest importance to use of ADT at present.  The amount of 
literature judged to contribute to this update is very small during the relevant period, and 
is limited to 12 reports including those on RCT and reviews.  Concerning issues (1) and 
(2), in particular, no new study results have been published (accepted).  Therefore, no 
updating has been performed regarding these 2 issues.  On the other hand, the guidelines 
have been revised to clearly recommend “consideration of CAB using bicalutamide” on 
the basis of one RCT and one analytical research study.  Concerning issue (4), the best 
time to start PADT, detailed analysis has been on the basis of 12 reports including 10 
RCTs.  Though the risk of death by cancer was reduced by 17% in patients with 
metastasis or progressive patients when ADT was started earlier, overall survival rate was 
not prolonged.  For recurrent prostate cancer, the guidelines recommend performance of 
clinical studies if possible.  Regarding issue (5), intermittent ADT, updating was 
performed on the basis of results of one RCT.  However, it has been concluded that the 
data are insufficient at present to recommend intermittent ADT in clinical practice. 
Large-scale clinical studies currently in progress are introduced in this ASCO update.  
They include 2 large-scale studies related to the time of initiation of ADT and 2 other 
large-scale studies related to intermittent ADT, which also intend to investigate QOL.  
The results of these studies are expected to demonstrate the role of ADT more clearly. 
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(V) Conservative management: Ambiguous interpretation as watchful waiting or active 
surveillance    
Recently, the concepts of watchful waiting and active surveillance have become subjects 
of discussion, and have (as so-called conservative management) been included among the 
choices recommended for patients with low-risk prostate cancer and elderly patients.  
The findings of large retrospective studies have provided the basis for this concept.  
However, reading of reports appearing in world-renowned medical reviews makes it clear 
that there is no clear distinction between conservative management and PADT for LPC, 
and that the description in this regard is ambiguous. 
According to the famous report by Albertesen et al. entitled “20-year outcomes following 
conservative management of clinically localized prostate cancer, JAMA 2006” 7), radical 
treatment is not necessary and conservative management is sufficient for low-risk or 
elderly patients.  However, in their study 42% of patients received endocrine therapy 
within 6 months after diagnosis.  According to the report by Miller et al.  (JNCI2006) 8), 
the initial treatment method in LPC was classified by age at time of diagnosis and biopsy 
grade, though appropriate treatment, that is, expectant management or PADT, was selected 
for only 45% of the low-risk group patients while the majority underwent prostatectomy 
and radiotherapy, which are considered excessive treatment.  The influence of reports 
appearing in well-read and famous medical reviews on clinical practice is not to be 
overlooked.  This report should be interpreted as handling PADT as an aggressive 
method of treatment with the outcome being influenced by PADT rather than regarding the 
report simply as an outcome of conservative management. This suggests the need for a 
randomized study of treatment of LPC and LAPC assigning subjects to immediate ADT 
and delayed ADT.  The author considers it unwise to too readily recommend watchful 
waiting or conservative management until the results of further study have been validly 
assessed. 
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(VI) Future of ADT 
A considerable number of malignant tumors are not localized to the organs of primary 
onset, and have already metastasized (clinically or microscopically) at the time of 
diagnosis.  Furthermore, surgery sometimes fails to completely extirpate LPC and LAPC, 
resulting in subsequent local recurrence and remote metastasis.  Systemic therapy is thus 
important in the treatment of cancer.  In the case of prostate cancer, ADT is a powerful 
means of systemic treatment.  Thanks to the success of a large-scale prostate cancer 
prevention trial (PCPT) 8) using the 5α reductase inhibitor finasteride, safe endocrine 
therapy that can maintain QOL has become possible.  The establishment of more 
powerful methods of ADT without impairment of QOL is expected not only for patients 
with progressive prostate cancer but also for LPC and LAPC, through the development of 
new antiandrogen preparations and molecular target drugs. 
It is important to promote basic and clinical research based on the understanding that cure 
of prostate cancer is almost always possible with current ADT if progression to the 
hormone independent prostate cancer can be avoided.  
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